Short answer
ROCKET PHARMACEUTICALS, INC. (RCKT) filed an 8-K current report with the SEC on August 3, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Boilerplate Regulation FD disclaimer, not substantive investor disclosure.
ROCKET PHARMACEUTICALS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Boilerplate Regulation FD disclaimer, not substantive investor disclosure
- No business, financial, or operational information provided in the excerpt
Item EX-99.1 · Exhibit EX-99.1
- Initial 3 patients safely received RP-A501 at 3.8 × 10¹³ GC/kg under the modified Phase 2 protocol
- No thrombotic microangiopathy, capillary leak syndrome, or other significant safety concerns observed
- FDA discussions underway on dosing additional patients and completing the 12-patient pivotal Phase 2 trial
- Regulatory pathway update and comprehensive Danon disease program update expected in the second half of 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ROCKET PHARMACEUTICALS, INC. 8-K filings
Get the next RCKT 8-K as it lands
Follow RCKT for push alerts, or ask the research agent what this filing means.